Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome

Autor: Marta Tonello, Paola Caramaschi, Cinzia Scambi, Sara Ugolini, Annalisa Castagna, Lucia De Franceschi, Elena Mattia, Michela Corbella, Ricciarda Raffaelli, Virginia Lotti, Amelia Ruffatti, Domenico Biasi, Oscar Bortolami
Rok vydání: 2018
Předmět:
0301 basic medicine
Adult
medicine.medical_specialty
Immunology
chemical and pharmacologic phenomena
CD59 Antigens
CD59
Complement Membrane Attack Complex
obstetric antiphospholipid syndrome
Membrane Cofactor Protein
03 medical and health sciences
0302 clinical medicine
Antiphospholipid syndrome
Pregnancy
Placenta
antiphospholipid syndrome
complement system
obstetric antiphospholipid syndrome
pregnancy complications
pregnancy outcome
medicine
Immunology and Allergy
Humans
Complement Activation
complement system
pregnancy outcome
030219 obstetrics & reproductive medicine
CD55 Antigens
CD46
Obstetrics
business.industry
Obstetrics and Gynecology
Plasma levels
medicine.disease
Antiphospholipid Syndrome
Complement system
Pregnancy Complications
Specific antibody
030104 developmental biology
medicine.anatomical_structure
Reproductive Medicine
Female
business
Zdroj: American journal of reproductive immunology (New York, N.Y. : 1989)REFERENCES. 82(6)
ISSN: 1600-0897
Popis: PROBLEM As antiphospholipid antibody-positive women with adverse pregnancy outcomes have higher plasma complement activation product levels, and the placentas of women with antiphospholipid syndrome (APS) exhibit C4d complement component deposition, complement activation involvement has been hypothesized in APS pregnancy complications. METHOD OF STUDY Plasma levels of C5a and C5b-9 complement components of 43 APS non-pregnant patients and 17 pregnant APS women were measured using enzyme-linked immunosorbent assay. The results were compared with those of 16 healthy non-pregnant women and eight healthy pregnant women, respectively. Placenta samples of five APS patients at high risk of pregnancy complications and of five healthy controls were subjected to immunoblotting analysis with specific antibodies to C5b-9 and CD46, CD55, CD59 complement regulators. RESULTS The mean plasma C5a and C5b-9 levels were significantly higher in the non-pregnant APS patients with previous thrombosis ± pregnancy morbidity (P = .0001 and P = .0034, respectively) and in the pregnant APS women with adverse outcomes (P = .0093 for both). Similarly, C5b-9 amounts were significantly higher in the adverse pregnancy outcome placenta (P = .0115) than in those associated to a favorable outcome. The mean CD46, CD55 and CD59 amounts were, instead, lower, although not always significantly, in the placentas of all the high-risk APS women with respect to the control placentas. CONCLUSION Data analysis demonstrated that there was significant complement activation in the more severe subset of APS patients and in only the adverse pregnancy outcome APS women. Further studies will clarify whether the lower CD46, CD55, and CD59 expressions in the APS placentas are limited to only high-risk APS patients.
Databáze: OpenAIRE
Externí odkaz: